Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Curr Eye Res ; 38(2): 278-82, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23330822

RESUMO

PURPOSE: To evaluate the efficacy of different anesthetics and topical anti-inflammatory treatment in patients undergoing intravitreal injections (IVI). METHODS: Prospective, randomized, double masked, comparative study. Patients undergoing 0.05 mL IVI were randomized to two different preoperative anesthetic regimes (regime A [0.5% tetracaine + naphazoline] versus regime B [5% lidocaine]) and two different post-injection topical protocols (protocol 1 [tobramycin qid] versus protocol 2 [tobramycin qid + diclofenac qid]). Patients were trained to score pain using a numerical rating pain scale from 0 (no pain) to 10 (excruciating pain) immediately after the injection, 30 min and 24 h later. Patients were instructed to take oral paracetamol (650-1000 mg, adjusted to the patient's weight) every six hours ad lib if necessary. RESULTS: A total of 156 patients were enrolled; 86 patients were randomized to regime A and 70 to regime B; 78 patients were assigned to each of the post-injection topical protocols. The average pain score immediately after the IVI was 2.77 (SD 2.12) for the whole group (2.85, SD 2.23 with tetracaine and 2.67, SD 2.00 with lidocaine; p = 0.73, Mann-Whitney U-test). Twenty-four hours later, the average pain score was 1.84, SD 2.45 (topical diclofenac + tobramycin) versus 1.75, SD 1.83 (topical tobramycin; p = 0.46, Mann-Whitney U-test). Forty-seven patients (30%) required oral paracetamol (average 3.3 and range 1-5 tablets). Conjunctival hemorrhage 30 min after the injection was less frequent and severe in eyes treated with topical naphazoline (p = 0.055, Mann-Whitney U-test). CONCLUSIONS: Topical tetracaine and lidocaine provide similar anesthesia before IVI. Topical diclofenac does not seem to reduce pain scores after IVI.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Dor Ocular/prevenção & controle , Injeções Intravítreas/efeitos adversos , Lidocaína/administração & dosagem , Doenças Retinianas/tratamento farmacológico , Tetracaína/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Anestésicos Locais/administração & dosagem , Inibidores da Angiogênese/administração & dosagem , Antibacterianos/administração & dosagem , Anti-Inflamatórios não Esteroides/administração & dosagem , Bevacizumab , Diclofenaco/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada , Dor Ocular/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nafazolina/administração & dosagem , Descongestionantes Nasais/administração & dosagem , Estudos Prospectivos , Ranibizumab , Tobramicina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA